• If you are wondering whether Bio-Rad Laboratories at around US$287.74 is priced attractively or not, it helps to step back and look at what the recent share performance and valuation checks are really saying.
• The stock has moved sharply, with a 16.2% gain over the past week, while returns for the past month and year to date are down 4.3% and down 5.7% respectively, and the 1 year return sits at 28.6% against declines of 24.1% over 3 years and 52.2% over 5 years.
• These mixed returns sit against a backdrop of ongoing interest in the life sciences tools and diagnostics space, where investors often weigh the value of established laboratory suppliers against newer peers. For Bio-Rad, that context matters because sentiment around testing equipment and reagent providers can shift quickly as funding trends, product cycles, or competitive developments come into focus.
• On Simply Wall St's 6 point valuation framework, Bio-Rad Laboratories scores a 2 out of 6, which suggests some checks flag possible undervaluation while others do not. The next step is to compare different valuation approaches and then look at a broader way of thinking about value later in the article.

Bio-Rad Laboratories scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Bio-Rad Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes the cash Bio-Rad Laboratories is expected to generate in the future and discounts those amounts back to a single value in today's dollars. It is essentially asking what those future cash flows are worth right now.

For Bio-Rad, the latest twelve month Free Cash Flow stands at about $343.4 million. Analysts provide explicit Free Cash Flow estimates out to 2030. Simply Wall St then extrapolates further annual projections beyond that point using its 2 Stage Free Cash Flow to Equity approach. By 2030, projected Free Cash Flow is $383.9 million, with intermediate years sitting between roughly $311.9 million and $486.6 million based on a mix of analyst inputs and modelled estimates.

Bringing all those projected cash flows back to today results in an estimated intrinsic value of $288.45 per share. Against a recent share price around $287.74, the model points to a very small 0.2% implied discount, which suggests the stock is effectively trading in line with this DCF estimate.

Result: ABOUT RIGHT

Bio-Rad Laboratories is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Bio-Rad Laboratories Price vs Earnings

For a profitable company, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. Investors typically accept a higher or lower P/E depending on what they expect for future growth and how risky they think those earnings are, so there is no single “right” number.

Bio-Rad Laboratories currently trades on a P/E of 45.62x. That sits above the Life Sciences industry average of 34.22x and below the peer group average of 57.04x. This shows how the market is pricing Bio-Rad’s earnings relative to other similar stocks, but it does not yet indicate what might be appropriate for this specific business.

Simply Wall St’s Fair Ratio concept aims to address that question. It estimates what P/E might be reasonable for Bio-Rad based on factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it is tailored to the company, the Fair Ratio of 15.53x can be more informative than a simple comparison with industry or peer averages. Comparing this 15.53x Fair Ratio with the actual 45.62x P/E indicates that the shares are trading above that company specific reference point on this metric alone.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Bio-Rad Laboratories Narrative

Earlier the article mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a clear story about Bio-Rad Laboratories to the numbers such as fair value, future revenue, earnings and margins, and then see how that story maps into a financial forecast and a fair value that you can compare with the current share price.

On Simply Wall St’s Community page, Narratives are available as an easy tool used by many investors. They allow you to pick or build a view, for example a more optimistic Bio-Rad Laboratories case with a fair value around US$320, or a more cautious case closer to US$293. You can then see how those different assumptions about revenue growth, profit margins, discount rates and future P/E ratios translate into different fair values that can help you decide whether the current price looks high or low against your chosen story.

Because Narratives are linked to live company data and are refreshed when new information such as earnings, buyback updates or analyst targets are added, your chosen Bio-Rad Laboratories story does not stay static but adjusts as facts change. This helps you regularly reassess whether the gap between fair value and price still supports your decision to hold, add or reduce exposure.

Do you think there's more to the story for Bio-Rad Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.